Entecavir With or Without Pegylated Interferon a-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B

The requested reference [9954b2d66af87d1d613f77a3e4fb7b433d3a3af9] no longer exists in our database. It has been replaced by the current reference: [80e8966b59ae29e096012faf2520f210fce22764]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.
Epistemonikos ID: 4fe4c2cbb10486a73a63597555966dac282d48cb
First added on: Jan 17, 2026